Cadrenal will present CAD-1005, a Phase 3-ready 12-LOX inhibitor for heparin-induced thrombocytopenia targeting $2 billion peak revenue, at BIO International Convention June 22–25. The company will also showcase tecarfarin, a late-stage oral vitamin K antagonist with orphan and fast track designations for ESRD, atrial fibrillation and LVAD patients.
Cadrenal will attend the BIO International Convention June 22–25 in San Diego, hosting executive meetings to discuss development and commercialization of its pipeline with potential partners.
CAD-1005 is a Phase 3-ready selective 12-LOX inhibitor for heparin-induced thrombocytopenia, completed an FDA End-of-Phase 2 meeting, holds orphan drug and fast track designations, and targets $2 billion in peak annual revenue.
The proprietary 12-LOX platform is being explored for inflammatory signaling in diseases including atherosclerosis, microvascular thrombosis, diabetes, obesity and potential cancer prevention, with second-generation oral candidates in preclinical development.
Tecarfarin, a late-stage oral vitamin K antagonist designed to minimize drug interactions and renal clearance issues, has orphan drug and fast track status for ESRD, atrial fibrillation and LVAD patients.
